Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 32 Myelodysplastic Syndromes 30 Leukemia, Myeloid, Acute 30 Multiple Myeloma 24 Lymphoma, Non-Hodgkin 24 Hodgkin Disease 24 Lymphoma 21 Leukemia 21 Graft vs Host Disease 21 Leukemia, Lymphocytic, Chronic, B-Cell 20 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16 Myeloproliferative Disorders 15 Lymphoma, Mantle-Cell 15 Neoplasms 14 Tuberous Sclerosis 13 Lymphoma, Large B-Cell, Diffuse 13 Hematologic Neoplasms 12 Burkitt Lymphoma 12 Primary Myelofibrosis 11 Lymphoma, Follicular 11 Breast Neoplasms 11 Waldenstrom Macroglobulinemia 10 Sarcoma 10 Recurrence 10 Neoplasms, Plasma Cell 10 Neoplasm Metastasis 10 Lymphoma, B-Cell, Marginal Zone 10 Leukemia, Myelomonocytic, Chronic 10 Prostatic Neoplasms 9 Lymphangioleiomyomatosis 9

Interventions

perampanel 1 Sirolimus 1 Immunoglobulins, Intravenous 1 Cannabidiol 1 Anticonvulsants 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Drug Resistant Epilepsy × Sirolimus × Clear all

NCT05534672 2023-08-08

RaRE-TS

Children's Memorial Health Institute, Poland

Phase 3 Recruiting

Drug Resistant Epilepsy, Epilepsy, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡